感染与未感染人类免疫缺陷病毒的成人中,非基因3型丙型肝炎病毒感染者肝脏脂肪变性程度低于两种病毒均未感染者
研究纳入356名成人,用磁共振成像和波谱测量肝脏脂肪分数,比较HCV单感染、HIV/HCV共感染、HIV单感染及无感染者。校正代谢与纤维化因素后,HCV单感染和HIV/HCV共感染与更低的肝脏脂肪分数相关,非基因3型HCV感染可能对肝脏脂肪变性有保护作用,机制及HCV治疗的影响需进一步研究。
要点
- 肝脏脂肪变性患病率在无感染者最高(33%),HIV单感染28%,HCV单感染19%,HIV/HCV共感染11%(组间P=0.003)。
- 校正人口学、生活方式和代谢因素后,HCV单感染和HIV/HCV共感染与更低的肝脏脂肪分数相关。
- 非基因3型HCV感染可能对肝脏脂肪变性有保护作用,但机制及HCV治疗的影响需进一步研究。
核心结论
- 与预期相反,HIV/HCV共感染和HCV单感染成人的肝脏脂肪显著少于无感染者,即使校正人口学、生活方式、代谢因素和肝纤维化后仍如此。
- 研究结果提示非基因3型HCV感染可能对肝脏脂肪变性有保护作用,其机制及HCV治疗对肝脏脂肪变性的影响需进一步研究。
研究设计与样本
- 横断面研究,纳入356名成人:HCV单感染57例、HIV/HCV共感染70例、HIV单感染122例、两种病毒均未感染107例。
- 排除HCV基因3型感染者;用磁共振成像和波谱测量内脏脂肪组织和肝脏脂肪分数(总脂质/[总脂质+水])。
- 肝脏脂肪变性定义为肝脏脂肪分数≥0.05;用多变量线性回归估计HIV和HCV状态与肝脏脂肪分数的关联,校正人口学、生活方式和代谢因素,包括HOMA-IR和APRI定义的肝纤维化。
主要发现
- 肝脏脂肪变性患病率:无感染者33%、HIV单感染者28%、HCV单感染者19%、HIV/HCV共感染者11%(组间P=0.003)。
- 与无感染者相比,校正人口学、生活方式和代谢因素后,HIV单感染、HCV单感染和HIV/HCV共感染分别与低19%(95%CI -39%至6%)、低38%(95%CI -55%至-12%)和低42%(95%CI -59%至-18%)的肝脏脂肪分数相关。
- HCV单感染和HIV/HCV共感染在进一步校正APRI后仍与更低的肝脏脂肪分数强相关,排除疑似肝硬化者后结果不变。
- 在整个队列中,西班牙裔、男性、内脏脂肪组织和HOMA-IR与更高的肝脏脂肪分数独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatic steatosis (HS) is common in individuals with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections, but the independent contributions of HCV and HIV to HS are unclear. Magnetic resonance imaging and spectroscopy were used to measure visceral adipose tissue (VAT) and liver fat fraction (LFF) (total lipids/[total lipids + water]) in 356 adults: 57 with HCV monoinfection, 70 with HIV/HCV coinfection, 122 with HIV monoinfection, and 107 with neither infection. Participants who were infected with HCV genotype 3 were excluded because of the genotype's reported steatogenic effects. For prevalence estimates, HS was defined as LFF ≥ 0.05. We estimated the association of HIV and HCV status with LFF using multivariable linear regression, adjusting for demographics, lifestyle, and metabolic factors including the homeostasis model assessment estimate of insulin resistance (HOMA-IR) and liver fibrosis defined using the aspartate aminotransferase-to-platelet ratio index (APRI). The prevalence of HS was highest in the uninfected (33%) and HIV-monoinfected (28%), followed by the HCV-monoinfected (19%) and HIV/HCV-coinfected (11%) (P = 0.003 across groups). Compared with uninfected participants-and after adjusting for demographics, lifestyle, and metabolic factors-HIV monoinfection, HCV monoinfection, and HIV/HCV coinfection were associated with 19% (95% confidence interval [CI], -39% to 6%), 38% (95% CI, -55% to -12%), and 42% (95% CI, -59% to -18%) lower LFF, respectively. HCV monoinfection and HIV/HCV coinfection remained strongly associated with lower LFF after further adjusting for APRI, and results were unchanged after excluding subjects with suspected cirrhosis. Among the entire cohort, Hispanic ethnicity, male sex, VAT, and HOMA-IR were independently associated with greater LFF. CONCLUSION: Contrary to expectations, HIV/HCV-coinfected and HCV-monoinfected adults had significantly less liver fat than uninfected adults, even after adjusting for demographics, lifestyle, metabolic factors, and hepatic fibrosis. Our findings suggest that non-genotype 3 HCV infection may be protective against HS. The mechanisms by which this occurs and the impact of HCV treatment on HS requires further investigation. (Hepatology 2017;65:853-863).
引用
- Price JC, Ma Y, Scherzer R, et al. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology. 2017. PMID: 27981599. doi:10.1002/hep.28968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。